Media Centre

WHO issues guidelines on skin and oral conditions in HIV adults and children

January 13 2015

In a quiet moment in late 2014, the World Health Organisation issued guidelines for the management of several HIV-related skin and oral diseases, in low resource settings. Led by Prof Rod Hay (International Foundation for Dermatology, London) and Toby Maurer (UCSF School of Medicine, San Francisco), all the clinical trial evidence for diagnosis and management was scrutinized using the Grade criteria, and recommendations made.

The conditions covered include the fungal conditions oral candidiasis, seborrhoeic, dermatitis, eosinophilic folliculitis and tinea infections and the non-fungal conditions Kaposi sarcoma, popular pruritic eruption, herpes zoster, scabies, mollucscum contagiosum,  Stevens-Johnson syndrome and toxic epidermal necrolysis.

The treatment recommendations can be summarized:

        Oral candidiasis

  • adults: Fluconazole 100-150mg/d for 7 days, or topical alternative
  • children: Fluconazole 3mg/Kg for 7-14 days, or topical therapy with clotimazole or nystatin

·         Seborrhoeic, dermatitis

  • mild: topical ketoconazole 2% 2-3 times weekly for 4 weeks, then weekly
  • severe: topical antifungals (ie ketoconazole 2%) and corticosteroid ointment

·         Eosinophilic folliculitis:

  • Oral antihistamine first. If no response add topical corticosteroid (ie betamethasone). If no response add itraconazole (200mg daily). If no response add permethrin 5% cream (above the waist).

·         Tinea infections

  •  localized: topical terbinafine 1% cream/gel for 2 weeks or miconazole topically for 4 weeks.
  • extensive or hair/nail invovement: oral griseofulvin or itraconazole 200mg daily, duration dependent on infection site.

(Separate recommendations are made with pregnancy).

The guidelines are here: and available online through the Maternal and Child Health division of WHO